Johnson & Johnson discontinued development of its geographic atrophy eye disease gene therapy JNJ-1887 after reviewing top-line phase 2b Parasol trial data. The company confirmed the geographic atrophy program will be discontinued and said learnings will be applied to its early-stage ophthalmology pipeline. J&J also communicated other pipeline changes in the wake of recent earnings updates, including removing assets tied to prior decisions and portfolio resets. For the industry, the decision illustrates how phase 2b readouts can force rapid portfolio reshaping in gene therapy, where timelines, manufacturing commitments, and trial restart risk create high stakes for each additional dataset.